Crossmark

Population pharmacokinetic modeling and dosing simulation of avalglucosidase alfa for selecting alternative dosing regimen in pediatric patients with late-onset pompe disease

Crossref DOI link: https://doi.org/10.1007/s10928-023-09874-8

Published Online: 2023-08-03

Published Print: 2023-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Tiraboschi, Gilles

Marchionni, David

Tuffal, Gilles

Fabre, David

Martinez, Jean-Marie

Haack, Kristina An

Miossec, Patrick

Kittner, Barbara

Daba, Nadia

Hurbin, Fabrice
Funding

Funding for this research was provided by:

Sanofi
License Information

Text and Data Mining valid from 2023-08-03

Version of Record valid from 2023-08-03
More Information

Article History

Received: 19 January 2023

Accepted: 8 July 2023

First Online: 3 August 2023

Declarations

:

: All authors are employees of Sanofi and may hold shares and/or stock options in the company.

Document is current

Any future updates will be listed below